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Summary
Background The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) has shown remyelinating activity 
in preclinical studies. We therefore assessed the safety and tolerability, and effi  cacy of opicinumab given soon after a 
fi rst acute optic neuritis episode.
Methods This randomised, double-blind, placebo-controlled, phase 2 study (RENEW) was done at 33 sites in Australia, 
Canada, and Europe in participants (aged 18–55 years) with a fi rst unilateral acute optic neuritis episode within 
28 days from study baseline. After treatment with high-dose methylprednisolone (1 g/day, intravenously, for 3–5 days), 
participants were assigned with a computer-generated sequence with permuted block randomisation (1:1) using a 
centralised interactive voice and web response system to receive 100 mg/kg opicinumab intravenously or placebo 
once every 4 weeks (six doses) and followed up to week 32. All study participants and all study staff , including the 
central readers, were masked to treatment assignment apart from the pharmacist responsible for preparing the study 
treatments and the pharmacy monitor at each site. The primary endpoint was remyelination at 24 weeks, measured 
as recovery of aff ected optic nerve conduction latency using full-fi eld visual evoked potential (FF-VEP) versus the 
unaff ected fellow eye at baseline. Analysis was by intention-to-treat (ITT); prespecifi ed per-protocol (PP) analyses 
were also done. This study is registered with ClinicalTrials.gov, number NCT01721161.
Findings The study was done between Dec 21, 2012, and Oct 21, 2014. 82 participants were enrolled, and 41 in each 
group comprised the ITT population; 33 participants received opicinumab and 36 received placebo in the PP 
population. Adjusted mean treatment diff erence of opicinumab versus placebo was −3·5 ms (17·3 vs 20·8 [95% CI 
−10·6 to 3·7]; 17%; p=0·33) in the ITT population, and −7·6 ms in the PP population (14·7 vs 22·2 [−15·1 to 0·0]; 
34%; p=0·050) at week 24 and −6·1 ms (15·1 vs 21·2 [−12·7 to 0·5]; 29%; p=0·071) in the ITT population and 
−9·1 ms (13·2 vs 22·4 [−16·1 to −2·1]; 41%; p=0·011) in the PP population at week 32. The overall incidence (34 [83%] 
of 41 in each group) and severity of adverse events (two [5%] of 41 severe adverse events with placebo vs three [7%] of 
41 with opicinumab) were similar between groups and no signifi cant eff ects on brain MRI measures were noted in 
either group (mean T2 lesion volume change, 0·05 mL [SD 0·21] for placebo vs 0·20 mL [0·52] with opicinumab; 
27 [77%] of 35 participants with no change in gadolinium-enhancing [Gd+] lesion number with opicinumab vs 
27 [79%] of 34 with placebo; mean 0·4 [SD 0·79 for the placebo group and 0·85 for the opicinumab group] new Gd+ 
lesions per participant in both groups). Treatment-related serious adverse events were reported in three (7%) of 
41 participants in the opicinumab group (hypersensitivity [n=2], asymptomatic increase in transaminase 
concentrations [n=1]) and none of the participants in the placebo group.
Interpretation Remyelination did not diff er signifi cantly between the opicinumab and placebo groups in the ITT 
population at week 24. However, results from the prespecifi ed PP population suggest that enhancing remyelination 
in the human CNS with opicinumab might be possible and warrant further clinical investigation.
Funding Biogen.
Introduction
Leucine-rich repeat and immunoglobulin domain-
containing neurite outgrowth inhibitor receptor-
interacting protein-1 (LINGO-1) is a negative regulator 
of oligodendrocyte diff erentiation and remyelination 
expressed on oligodendrocytes and neurons of the 
CNS.1 LINGO-1 antagonism enhances remyelination in 
vitro and in animal models of CNS demyelination, 
including lysolecithin injection into the rat spinal cord, 
cuprizone demyelination of mouse brain, and rat 
autoimmune encephalomyelitis.2–4 LINGO-1 blockade 
might also aff ord neuroprotection independently of 
remyelination as suggested by evidence from rodent 
models of glaucoma, spinal cord injury, and 
dopaminergic cell toxicity.1
Acute optic neuritis frequently occurs in multiple 
sclerosis as the fi rst manifestation. Infl ammatory 
demyelination and axonal injury occur, and despite some 
spontaneous remyelination, most patients are left with 
residual structural and clinical defi cits associated with 
nerve conduction abnormalities that can be quantifi ed by 
electrophysiological measures.5,6 Current treatments for 
acute optic neuritis are typically high-dose intravenous 
corticosteroids7 and plasma exchange.8 Multiple sclerosis 
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is usually treated with anti-infl ammatory disease-
modifying therapies to reduce the frequency and severity 
of future recurrent attacks,9 but such therapies cannot 
repair neuronal damage. Therefore, development of 
therapies facilitating remyelination, neuroprotection, and 
neuron repair or axonal regeneration remains an 
important unmet need.9
Opicinumab (BIIB033, anti-LINGO-1) is a human 
monoclonal antibody engineered into an aglycosyl 
immunoglobulin G subclass 1 framework to reduce 
eff ector function.10 Opicinumab has proven eff ective in 
preclinical remyelination and neuroprotection rodent 
models, independent of infl ammation,1 and good initial 
tolerability and safety have been shown in phase 1 studies 
of healthy volunteers and adults with multiple sclerosis.10
We assessed for the fi rst time in human beings the 
safety and tolerability, and the effi  cacy of opicinumab 
initiated soon after a fi rst acute optic neuritis episode.
Methods
Study design and participants
This randomised, double-blind, placebo-controlled study 
(RENEW) was done at 33 sites across Australia, Canada, 
and Europe.
The study was done in accordance with the 
International Conference on Harmonisation Good 
Clinical Practice guidelines and the Declaration of 
Helsinki. All investigators obtained approval from their 
local ethics committee before study start.
Eligible participants were aged 18–55 years, had a fi rst 
unilateral onset of acute optic neuritis within 28 days 
from fi rst symptom onset, and received treatment with 
1 g methylprednisolone per day intravenously for 
3–5 days before randomisation. The diagnosis of acute 
optic neuritis required the presence of at least two of 
the following: reduced visual acuity; aff erent pupillary 
defect; colour vision loss; visual fi eld abnormality; and 
Research in context
Evidence before this study
We searched PubMed up to March 15, 2016, without language 
or other restrictions. RENEW was designed as a 
proof-of-concept study in acute optic neuritis as an in-vivo 
system to investigate the eff ect on visual evoked potential 
(VEP) latency of opicinumab (anti-LINGO-1, BIIB033). To 
identify previous investigations of remyelination or potential 
remyelinating agents, we used the terms “optic neuritis” OR 
“multiple sclerosis” AND “clinical trial” AND “remyelination”; 
“remyelination” AND “visual evoked potential”. These searches 
identifi ed several articles discussing imaging techniques with 
potential for assessing remyelinating or neuroreparative 
therapies, reviews of novel agents for treating multiple 
sclerosis, trials of intravenous immunoglobulins in multiple 
sclerosis, pilot studies of insulin-like growth factor-1 in 
multiple sclerosis, and the remyelinating potential of 
intravenous immunoglobulins in multiple sclerosis. Several 
studies in rodents and longitudinal analysis of patients with 
optic neuritis using VEP were also identifi ed. However, no 
reports of previous multicentre randomised controlled trials of 
a potential remyelinating agent were found. We therefore did a 
further search using the terms “optic neuritis” AND “visual 
evoked potential” AND “clinical trial” to identify any studies 
with a similar study population that used VEP as an outcome 
measure to assess treatment effi  cacy. This search identifi ed 
45 publications, of which three assessed intravenous 
immunoglobulin, erythropoietin, or simvastatin in participants 
with optic neuritis using VEP as an outcome. Finally, we 
searched ClinicalTrials.gov using the terms “optic neuritis” AND 
“visual evoked potential” to identify potential trials, and 
PubMed for associated publications using the trial number and 
name of the responsible party or principal investigator. We 
identifi ed a study of the potential neuroprotective eff ects of 
phenytoin in participants with optic neuritis in which VEP was 
a secondary endpoint. These reports from single-centre or 
single-country studies suggested that simvastatin might have 
an eff ect on VEP latency, but no treatment eff ects, as measured 
by VEP latency, were found with erythropoietin, intravenous 
immunoglobulin, or phenytoin.
Added value of this study
This is the fi rst multicentre clinical trial investigating the 
effi  cacy of opicinumab on VEP latency. Therapies facilitating 
remyelination, neuroprotection, or neuron 
repair or regeneration remain an unmet need for CNS 
demyelinating disorders, and opicinumab was developed as a 
potential remyelinating agent. Furthermore, novel outcome 
measures are required to assess remyelination in addition to 
the clinical outcomes traditionally used. In the RENEW study, 
participants treated with opicinumab show some 
improvement in conduction latency recovery versus placebo, 
but the diff erence in the intention-to-treat population at 
24 weeks was not signifi cant. Our data provide some evidence 
that supports further clinical investigation of opicinumab as 
the prespecifi ed per-protocol population and responder 
analyses showed better recovery with opicinumab than with 
placebo. The results also confi rm the feasibility of including 
patients with a fi rst acute optic neuritis episode as a target 
population to test novel CNS remyelinating agents and of 
using full-fi eld VEP latency as the primary endpoint in 
international studies.
Implications of all the available evidence
Some fi ndings from our study as well as those of 
Raftopoulos and colleagues (2016) suggest that it might be 
possible to prevent neuronal loss and to enhance 
remyelination following an initial episode of acute optic 
neuritis. Our results also lend support to the further 
investigation of the safety and effi  cacy of opicinumab in 
patients with multiple sclerosis. 
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pain on eye movement, and was confi rmed by study 
investigators. Visual evoked potential (VEP) alterations 
were not a diagnostic criterion for acute optic neuritis, 
but fellow eye VEP latency abnormality was an 
exclusion criterion (see below). Enrolment was allowed 
irrespective of whether demyelinating lesions were 
present on brain MRI, and acute optic neuritis was 
accepted as the fi rst sign of (newly diagnosed) multiple 
sclerosis. Exclusion criteria were previous episode of 
optic neuritis or previous CNS demyelinating event 
indicative of multiple sclerosis; an established diagnosis 
of multiple sclerosis (previous to acute optic neuritis 
onset); refractive errors of –6 dioptres to +6 dioptres or 
more in either eye; loss of vision not due to acute optic 
neuritis; an abnormal full-fi eld VEP (FF-VEP) in the 
fellow eye at screening; and a concomitant ophthal-
mological disorder (as determined by a physician with 
expertise in the diagnosis and treatment of 
ophthalmological disorders, using any assessments felt 
to be necessary to exclude an alternative diagnosis, and 
based on their expertise and local standard of care)—
eg, diabetic retinopathy, macular degeneration, macular 
exudate, macular oedema, glaucoma, severe astig-
matism, ocular trauma, neuromyelitis optica, ischaemic 
optic neuropathy, congenital nystagmus, or other 
ophthal mological conditions that could confound the 
assessment of functional and anatomical endpoints. 
Participants with a history or evidence of any of the 
following were also excluded: severe disc oedema or 
haemorrhage; any clinically signifi cant cardiac, endo-
crinological, haematological, hepatic, immuno logical, 
metabolic, urological, pulmonary, neurological, 
dermato l ogical, psychiatric, oncological, renal, severe 
allergic or anaphylactic reactions, or other major 
disease; HIV, hepatitis C, or hepatitis B infection; and 
drug or alcohol abuse in the past 2 years. Participants 
were excluded if they had been enrolled in another 
study within the past 3 months or participated in a 
previous study with opicinumab, were unable to comply 
with study requirements, or if the investigator felt there 
were other reasons making participation unsuitable. 
Women were excluded if pregnant, breastfeeding, or 
planning to conceive during the study.
All participants provided written informed consent.
Randomisation and masking
Participants were randomly assigned (1:1) to placebo or 
opicinumab. The allocation sequence was computer 
generated and randomisation was achieved via a permuted 
block method using a centralised interactive voice and 
web response system. The block size was four and the 
number of blocks was 50. A Biogen biostatistician was 
responsible for overseeing the randomisation and only the 
pharmacists preparing treatments or pharmacy monitors 
were unmasked. Masking was achieved by infusing the 
same volumes of saline over the same duration regardless 
of whether the infusion bags contained opicinumab or 
not. Furthermore, all saline bags were covered with a dark 
bag before leaving the pharmacy.
Procedures
Participants received opicinumab (100 mg/kg 
intravenously) or placebo every 4 weeks from baseline to 
week 20 (six treatments) and assessed up to week 32 
(appendix p 3). 100 mg/kg was the highest dose tested in 
previous phase 1 studies; it was well tolerated, and 
selected because this study required a concentration 
greater than EC90 (90% eff ective concentration) as the 
target effi  cacious concentration of opicinumab for the 
human brain is unknown and, under normal conditions, 
LINGO-1 concentrations in rat CNS (the pharmacology 
animal model) are lower than in humans.1 FF-VEP, 
spectral-domain optical coherence tomography 
(SD-OCT), and low-contrast letter acuity were assessed at 
screening, baseline, and every 4–8 weeks to study end 
(week 32) to assess effi  cacy.
For FF-VEP measurements, the participant was seated 
70–150 cm away from the stimulus (consistent distance 
at the site level throughout the trial) and then FF-VEP 
was done with a black and white checkerboard and a 60ʹ 
check stimulus size. Stimulus screen luminance and 
contrast were constant throughout the study. Electrodes 
were placed according to the Queen Square System and 
four channels were monitored: left occipital to midfrontal; 
midoccipital to midfrontal; right occipital to midfrontal; 
and midfrontal to ear or mastoid. P100 latency was 
determined from the midoccipital site, where amplitude 
is maximal.
Because this was the fi rst multicentre study to use VEP 
latency as a primary endpoint, a rigorous process was 
followed to ensure reproducibility and consistency. All 
centres were required to undertake all FF-VEP 
assessments using a standard protocol developed by the 
Duke Reading Center (Duke University, Durham, NC, 
USA) to comply with both the International Society for 
Clinical Electrophysiology of Vision and the American 
Clinical Neurophysiology Society guidelines. Detailed 
instructions on all aspects of VEP training, recording, and 
submission of data to the central reader for evaluation and 
assessment of eligibility (on the fellow eye) and for effi  cacy 
on the primary endpoint were provided to study site 
investigators. Before study initiation at the site, each 
technician had to be certifi ed to do VEP according to the 
study protocol. For certifi cation, technicians were required 
to submit VEP studies using the standard protocol on 
two people, each studied on two separate occasions. The 
submitted VEP studies were assessed by trained Duke 
Reading Center VEP readers who ensured that the VEP 
data were submitted according to study protocol. All data 
reported were obtained using the Duke Reading Center 
standard protocol. Site-specifi c techniques and normative 
data were used only at the screening visit to determine 
normalcy of the participants’ fellow eye latency, as required 
by the protocol. Each VEP study was interpreted 
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independently by two masked clinical electrophysiologists. 
If the data agreement was not within specifi ed parameters, 
a third masked independent clinical electrophysiologist 
arbitrated the data by reconciling the reader disagreements 
according to his or her best judgment and expertise, and 
provided the fi nal interpretation. Each VEP measure was 
interpreted without reference to any of the participant’s 
other VEP data. Central readers were not involved in 
data collection or analysis.
Study sites were also certifi ed by the Duke Reading 
Center to obtain SD-OCT scans according to a standardised 
study protocol. The appendix (p 2) contains details of the 
protocol, data analysis, and quality control procedures.
Outcomes
The primary endpoint was optic nerve conduction 
velocity measured by FF-VEP (peak found around 
100 ms on the standard VEP in healthy adults [P100]) 
latency at end of treatment (week 24) in the aff ected 
eye, compared with the unaff ected eye at baseline. This 
technique measures electrophysiological responses to 
patterned visual stimuli:11 prolongation of VEP latency 
is associated with infl ammatory demyelination in acute 
optic neuritis, whereas subsequent latency shortening 
can occur as a result of resolution of infl ammation 
(believed to occur earlier on) and spontaneous 
remyelination (believed to occur later on).12 A fi nal 
latency assessment, as a supportive analysis, was done 
at study end (week 32).
Secondary endpoints studied another potential 
opicinumab mechanism of action, the acute neuro-
protection of retinal ganglion cells (RGCs) and their 
axons. Secondary effi  cacy endpoints assessed at week 24 
were change in RGC layer/inner plexiform layer (RGCL/
IPL) thickness in the aff ected eye compared with the 
unaff ected eye at baseline measured by SD-OCT; 
percentage change in retinal nerve fi bre layer (RNFL) 
thickness in the aff ected eye versus the unaff ected eye at 
baseline measured by SD-OCT; and change in low-
contrast letter acuity of the aff ected eye from baseline 
measured using 1·25% and 2·5% Sloan letter charts; 
the aff ected eye’s own baseline value was used as the 
baseline covariate.
Additional analyses, based on FF-VEP latency, were 
number of participants with FF-VEP latency recovery, 
defi ned as aff ected eye FF-VEP latency 10% or less worse 
than the fellow eye, at week 24 in the per-protocol (PP) and 
intention-to-treat (ITT) populations (prespecifi ed); also, a 
post-hoc sensitivity analysis around this recovery threshold 
was done on the ITT and PP populations to assess whether 
10% was an appropriate cutoff . We also assessed mean 
change in FF-VEP latency at week 24 between treatment 
groups (ITT population) for participants who received at 
least four infusions (post-hoc).
All images were assessed centrally for quality control.
Adverse event monitoring was done from 
administration of fi rst study dose to week 32, and 
serious adverse event monitoring from screening to 
week 32. Safety assessments at screening, baseline, and 
every 4–8 weeks up to week 32 were: physical 
examination and vital signs; and haematology, blood 
chemistry, and urinalysis. Participants also had a brain 
MRI scan (with and without gadolinium [Gd+] 
enhancement) at screening and week 32; 12-lead electro-
cardiogram at screening and weeks 24 and 32; 
assessment of acute optic neuritis signs and symptoms 
at screening, baseline, and weeks 12, 24, and 32; and 
measurement of blood drug and anti-opicinumab 
antibody levels every 4–8 weeks from baseline to week 32 
as part of the pharmacokinetic and safety assessments.
Statistical analysis
The effi  cacy and safety analyses included all randomised 
participants who received at least one dose of study 
Figure 1: Trial profi le
ITT=intention-to-treat. AON=acute optic neuritis. PP=per-protocol. VEP=visual evoked potential.
100 assessed for eligibility
82 randomly assigned
41 assigned to placebo (ITT) 41 assigned to 100 mg/kg 
 opicinumab (ITT)
4 discontinued study drug
 1 consent withdrawal
 1 adverse event
 1 lost to follow-up
 1 other
4 withdrew from study
 1 consent withdrawal
 2 adverse event
 1 lost to follow-up
5 discontinued study drug
 1 consent withdrawal
 3 adverse event
 1 other
7 withdrew from study
 1 consent withdrawal
 3 adverse event
 2 lost to follow-up
 1 other
37 completed treatment
37 completed study
 3 completed but missed ≥1 dose
36 assigned to placebo (PP)
 4 participants did not complete the study
 1 missed >1 dose
36 completed treatment
34 completed study
33 assigned to 100 mg/kg 
 opicinumab (PP)
 6 participants did not complete the study
 1 did not complete the study and missed 
 >1 dose
 1 received multiple sclerosis modifying 
 therapy
18 excluded
 6 consent withdrawn
 5 diagnosis of AON not established
 5 screening VEP eligibility not met
 1 maculopathy
 1 unspecified increased laboratory results
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treatment (ITT population). A second prespecifi ed 
population assessed for effi  cacy comprised participants 
who completed the study, missed no more than one 
study dose, and did not receive multiple sclerosis-
specifi c disease-modifying therapies (prohibited per 
protocol). These criteria were selected to ensure a 
population was assessed that had received adequate 
dosing and a suffi  cient length of follow-up; this enabled 
analysis of biological activity without the imputations 
inherent for early discontinuations in the primary 
analysis on the ITT population.
When designing the study, the chosen sample size was 
selected (about 40 participants per treatment group) to 
have about 80% power to detect a treatment diff erence 
between opicinumab and placebo with a one-sided t test 
(α=0·1) if the treatment eff ect for improvement of VEP 
latency was at least 50%.
Participant demographics, clinical characteristics, 
and safety data were summarised with descriptive 
statistics. For the effi  cacy endpoints, adjusted mean 
change (with SE at week 24) was calculated and 
between-treatment comparisons were evaluated with 
ANCOVA at week 24 and mixed-eff ect model repeated 
measure through week 32. Week 32 data were used as a 
supportive analysis to check whether treatment eff ect 
was sustained between end of treatment (week 24) and 
end of study (week 32). Last observation carried forward 
(LOCF) was used to impute missing data at week 24 in 
the ANCOVA.
The percentage of participants with versus without 
FF-VEP latency recovery was compared between 
treatment groups using a χ² test; both χ² and Fisher’s 
exact tests were used for the sensitivity analyses for the 
10% cutoff . Data were analysed with SAS version 9.3. 
Intention-to-treat population Per-protocol population
Placebo (n=41) Opicinumab (n=41) All participants 
(n=82)
Placebo (n=36) Opicinumab (n=33) All participants 
(n=69)
Women 31 (76%) 27 (66%) 58 (71%) 27 (75%) 21 (64%) 48 (70%)
White 39 (95%) 40 (98%) 79 (96%) 35 (97%) 32 (97%) 67 (97%)
Age (years) 32·4 (8·9) 31·8 (7·2) 32·1 (8·0) 32·2 (8·8) 31·2 (7·1) 31·7 (8·0)
Weight (kg) 75·0 (47–119) 71·2 (46–106) 72·2 (46–119) 73·8 (50–119) 72·2 (46–106) 72·5 (46–119)
Height (cm)* 169·0 (155–194) 170·0 (158–188) 170·0 (155–194) 169·5 (155–194) 170·0 (158–188) 170·0 (155–194)
Days from fi rst AON symptom to fi rst dose† 24·6 (3·4) 23·6 (4·0) 24·1 (3·7) 24·3 (3·5) 24·0 (3·8) 24·2 (3·6)
Days from confi rmed AON diagnosis to fi rst dose 19·2 (4·9) 18·7 (4·7) 19·0 (4·8) 19·1 (5·0) 19·2 (4·6) 19·1 (4·7)
Participants with aff ected right eye 19 (46%) 25 (61%) 44 (54%) 16 (44%) 20 (61%) 36 (52%)
Criteria for AON diagnosis
Decreased visual acuity 36 (88%) 41 (100%) 77 (94%) 31 (86%) 33 (100%) 64 (93%)
Decreased colour vision 30 (73%) 33 (80%) 63 (77%) 27 (75%) 26 (79%) 53 (77%)
Relative aff erent pupillary defect 34 (83%) 31 (76%) 65 (79%) 29 (81%) 23 (70%) 52 (75%)
Visual fi eld defect 32 (78%) 37 (90%) 69 (84%) 27 (75%) 30 (91%) 57 (83%)
Ocular pain 31 (76%) 36 (88%) 67 (82%) 27 (75%) 28 (85%) 55 (80%)
Other 5 (12%) 4 (10%) 9 (11%) 5 (14%) 4 (12%) 9 (13%)
AON signs and symptoms at screening or baseline visit‡
Visual fi eld defect 29 (71%) 34 (83%) 63 (77%) 25 (69%) 27 (82%) 52 (75%)
Colour desaturation 33 (80%) 32 (78%) 65 (79%) 28 (78%) 25 (76%) 53 (77%)
Uhthoff ’s symptom 8 (20%) 18 (44%) 26 (32%) 6 (17%) 16 (48%) 22 (32%)
Swollen optic disc 8 (20%) 12 (29%) 20 (24%) 6 (17%) 11 (33%) 17 (25%)
Relative aff erent pupillary defect 33 (80%) 30 (73%) 63 (77%) 28 (78%) 24 (73%) 52 (75%)
FF-VEP conduction block in the aff ected eye at baseline 5 (12%) 10 (24%) 15 (18%) 5 (14%) 6 (18%) 11 (16%)
FF-VEP latency in the fellow eye at baseline (ms) 101·7 (5·3) 102·7 (6·4) 102·2 (5·8) 101·0 (4·9) 102·6 (6·1) 101·8 (5·5)
RGCL/IPL thickness in the aff ected eye at baseline (μm)§ 66·0 (6·9) 63·8 (7·4) 64·8 (7·2) 65·9 (7·2) 63·6 (8·1) 64·8 (7·7)
Number of participants with Gd+ lesions before fi rst dose¶ 7 (18%) 2 (5%) 9 (12%) 5 (15%) 1 (3%) 6 (9%)
Number of brain Gd+ lesions before fi rst dose¶ 0·5 (1·6) 0·2 (1·0) 0·4 (1·4) 0·2 (0·7) 0·1 (0·4) 0·1 (0·5)
Number of participants with T2 lesions before fi rst dose¶ 32 (84%) 29 (76%) 61 (80%) 29 (85%) 25 (76%) 54 (81%)
Volume of brain T2 lesions before fi rst dose (mL)¶ 1·09 (1·32) 1·09 (1·90) 1·09 (1·63) 0·95 (1·03) 0·84 (1·55) 0·89 (1·30)
AON=acute optic neuritis. FF-VEP=full-fi eld visual evoked potentials. Gd+=gadolinium-enhancing. RGCL/IPL=retinal ganglion cell layer/inner plexiform retinal layer. ITT=intention-to-treat. PP=per-protocol.  
*n=39 in each group; total n=78 for the ITT population; n=34 in the placebo group; n=31 in the opicinumab group; total n=65 in the PP population. †First dose given, on average, 2 weeks after completion of 
high-dose intravenous methylprednisolone treatment (1 g daily for 3–5 days). ‡Symptoms were not uniformly tested in accordance with a predefi ned protocol. §n=38 in the placebo group and n=40 in the 
opicinumab group, total=78 for the ITT population; n=34 in the placebo group and n=32 in the opicinumab group, total=66 for the PP population. ¶n=38 in each group, total=76 for the ITT population; n=34 in 
the placebo group and n=33 in the opicinumab group, total=67 for the PP population. 
Table 1: Demographic and clinical characteristics of participants
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An internal safety monitoring committee (comprising 
manuscript coauthors [DC, SF, and LX]) oversaw 
the study.
Due to reading diff erences between Cirrus (Carl Zeiss 
Meditec, Dublin, CA, USA) and Spectralis (Heidelberg 
Engineering, Heidelberg, Germany) manufacturing 
analysis software, RNFL thinning was reported as a 
percentage. By contrast, a value in μm was used for 
RGCL/IPL thinning because the reading centre analysis 
software gives identical results with both Cirrus and 
Spectralis scans.
This study is registered with ClinicalTrials.gov, number 
NCT01721161.
Role of the funding source
The funder of the study was involved in the study design, 
conduct, data analysis, and data interpretation, drafting 
and review of the report, and the decision to submit for 
publication, all in collaboration with the coauthors. The 
corresponding author had full access to all data from the 
study (along with the coauthors) and had fi nal 
responsibility for the decision to submit the manuscript.
Results
The study was done between Dec 21, 2012, and Oct 21, 2014. 
100 participants were screened and of these 82 participants 
were randomly assigned to placebo or opicinumab at 
33 sites across Australia, Canada, and Europe. Median 
number of participants per site was two (mode one, 
range 1–7). The ITT population comprised 41 participants 
in each treatment group, whereas in the PP 
population 33 received opicinumab and 36 placebo 
(fi gure 1). The groups had similar baseline demographics 
(table 1), participants withdrawing from the study, and 
treatment discontinuation (fi gure 1). However, severe 
cases of acute optic neuritis were randomised more 
frequently to the opicinumab group than to the placebo 
group as shown by the prevalence of conduction block (2:1, 
respectively) and presence of several acute optic neuritis 
signs and symptoms at screening or baseline (table 1).
Improvement in optic nerve conduction velocity 
(primary endpoint) was indicated by shorter latency. The 
results showed some shortening of latency with 
opicinumab versus placebo in the ITT population at 
week 24 (adjusted mean of treatment diff erence: −3·5 ms 
[17·3 (SE 2·5) vs 20·8 (2·5); 95% CI −10·6 to 3·7; p=0·33], 
17% improvement) and week 32 (−6·1 ms [15·1 vs 21·2; 
95% CI −12·7 to 0·5; p=0·071], 29% improvement). The 
diff erence was signifi cant in the PP population at week 32 
(−9·1 ms [13·2 vs 22·4; 95% CI −16·1 to −2·1; p=0·011], 
41% improvement; fi gure 2A) but not at week 24 (−7·6 ms 
[14·7 (SE 2·7) vs 22·2 (2·6); 95% CI −15·1 to 0·0; 
p=0·050], 34% improvement).
No treatment eff ect was noted for the secondary effi  cacy 
endpoints of RNFL and RGCL/IPL thickness by SD-OCT 
or change in low-contrast letter acuity for placebo versus 
opicinumab at week 24 (table 2). However, most RGCL/
IPL thinning occurred before the fi rst administration of 
the study dose and all RGCL/IPL thinning had occurred 
before the second dose was given in week 4 (table 1, 
fi gure 2B, appendix p 5; corresponding fellow eye data 
are given on appendix p 6).
The numbers and proportions of participants with an 
adverse event and severity of adverse events were similar 
between placebo and opicinumab, with 34 participants in 
each group (83%) having at least one adverse event 
(table 3). Five adverse events occurred in 10% or more of 
participants: fatigue, nausea, headache, nasopharyngitis, 
and Uhthoff ’s phenomenon (table 3).
The number of participants with a serious adverse 
event or discontinuing treatment was higher in the 
Figure 2: Change in VEP latency (A) and OCT thickness (B) outcomes
Adjusted mean change in optic nerve conduction latency was measured by FF-VEP in the aff ected eye compared 
with the unaff ected fellow eye at baseline in the PP and ITT populations at week 24 (by ANCOVA) and week 32 
(by MMRM). Mean (SD) RGCL/IPL thickness at each visit was measured by spectral-domain optical coherence 
tomography in the aff ected eye in the PP population up to week 32. PP=placebo, n=36; opicinumab, n=33. ITT: 
n=41, both groups. FF-VEP=full-fi eld visual evoked potential. ITT=intention-to-treat. MMRM=mixed-eff ect model 
repeated measure. PP=per-protocol. RGCL/IPL=retinal ganglion cell layer/inner plexiform layer. SEs were not 
calculated for week 32 data.
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opicinumab group (table 3). Of the two participants (5%) 
in the placebo group who had a serious adverse event, 
one had viral pericarditis and tested positive for 
cytomegalovirus and one developed multiple sclerosis. 
Of the fi ve participants (12%) in the opicinumab group 
who had serious adverse events, one participant had a 
multiple sclerosis relapse and one had optic neuritis in 
the fellow eye; two cases of hypersensitivity reactions that 
occurred shortly after the start of the second infusion and 
one asymptomatic case of increased alanine and aspartate 
aminotransferases (reported as hepatopathy and fi rst 
observed after the second infusion) were considered 
treatment related. The three participants with treatment-
related serious adverse events in the opicinumab group 
discontinued treatment in addition to the placebo-treated 
participant who developed multiple sclerosis (table 3). All 
serious adverse events reported as treatment related 
resolved on treatment discontinuation.
The incidence of adverse events by System Organ Class 
(SOC) was generally similar between groups and the SOCs 
with the most frequent events (≥10% of total participants) 
are presented in table 3. Events in the gastrointestinal SOC 
occurred more frequently (≥10% diff erence) in participants 
in the opicinumab group (12 [29%]) than in the placebo 
group (fi ve [12%]). The most commonly reported 
gastrointestinal symptoms were nausea (fi ve [12%] in the 
opicinumab group vs three [7%] in the placebo group) and 
dyspepsia (two [5%] vs one [2%]).
The number of participants with an adverse event 
occurring within 4 h after the start of an infusion was 
higher in participants in the opicinumab group than in 
those in the placebo group (appendix p 7). The same 
event did not occur with every infusion (data not shown). 
Adverse events were most frequent after the second and 
third infusions, and the most common infusion-related 
adverse events in the opicinumab group were headache 
(three [7%]) and nausea (three [7%]), and in the placebo 
group was dysgeusia (one [2%]).
17 participants had weight gain of more than 7% from 
baseline: four from the placebo group (10%) and 13 from 
the opicinumab group (32%). Three participants had 
weight decrease of more than 7% (two in the placebo 
group vs one in the opicinumab group). Mean change in 
weight and percentage change from baseline at week 24 
in the placebo group were 0·69 kg (SD 2·15) and 
0·81% (2·88), and in the opicinumab group were 2·88 kg 
(3·56) and 3·86% (4·85). No participants died in either 
the opicinumab or placebo group.
Other safety and tolerability investigations were similar 
between groups and no immunogenicity was noted. 
No evidence of worsening of T2 lesion volume was 
shown (mean 0·05 mL [SD 0·21]; median 0·017 
[IQR 0·000–0·146] in the placebo group vs 0·20 mL 
[0·52]; median 0·003 [IQR 0·000–0·232] in the 
opicinumab group), or change in Gd+ lesion number 
(0·14 [0·73; 27 (77%) of 35 participants had no change] in 
the placebo group vs 0·32 [0·81; 27 (79%) of 34] in the 
opicinumab group) from screening to week 32 (appendix 
p 8). Additionally, minimal enhancing activity was noted 
in both groups at week 32 (mean 0·4 new Gd+ lesions 
per participant in both groups [0·4 (SD 0·79) in the 
placebo group vs 0·4 (0·85) in the opicinumab group]).
In a post-hoc analysis of participants from the ITT 
population who received at least four infusions, 
improvement in FF-VEP latency at week 24 was similar to 
the primary endpoint analysis for the PP population 
Intention-to-treat analyses Per-protocol analyses
Placebo (n=41) Opicinumab (n=41) Placebo (n=36) Opicinumab (n=33)
Mean percentage change (SE) in RNFL thickness (SD-OCT)*; 
aff ected eye at week 24 vs baseline fellow eye
−11·8 (2·1) −15·7 (2·0) −12·2 (2·3) −17·0 (2·3)
Treatment diff erence at week 24 vs placebo (95% CI)* −3·9 (−9·7 to 1·9) ·· −4·8 (−11·3 to 1·7) ··
p value 0·19 ·· 0·15 ··
Mean change (SE) in RGCL/IPL thickness (μm)*; aff ected eye at 
week 24 vs baseline fellow eye
−9·9 (1·2) −11·1 (1·2) −10·2 (1·3) −11·9 (1·4)
Treatment diff erence at week 24 vs placebo (95% CI)* −1·2 (−4·5 to 2·2) ·· −1·8 (−5·5 to 2·0) ··
p value 0·50 ·· 0·35 ··
Mean change (SE) in LCLA (1·25% Sloan chart)†; aff ected eye at 
week 24 vs baseline
8·1 (1·8) 6·5 (1·9) 7·2 (1·8) 6·0 (2·0)
Treatment diff erence at week 24 vs placebo (95% CI)† −1·6 (−6·9 to 3·6) ·· −1·2 (−6·6 to 4·3) ··
p value 0·54 ·· 0·66 ··
Mean change (SE) in LCLA (2·5% Sloan chart)†; aff ected eye at 
week 24 vs baseline
11·9 (2·0) 11·0 (2·0) 11·6 (2·0) 10·8 (2·2)
Treatment diff erence at week 24 vs placebo (95% CI)† −0·8 (−6·5 to 4·9) ·· −0·8 (−6·7 to 5·2) ··
p value 0·77 ·· 0·80 ··
RNFL=retinal nerve fi bre layer. RGCL/IPL=retinal ganglion cell layer/inner plexiform retinal layer. SD-OCT=spectral-domain optical coherence tomography. LCLA=low-contrast 
letter acuity. *A decrease (negative value) represents loss of RNFL thickness; the diff erence versus placebo represents the more severe acute optic neuritis evident pretreatment 
initiation in the opicinumab group (table 1). †An increase in LCLA from baseline represents recovery; a negative diff erence versus placebo indicates no treatment eff ect. 
Table 2: Secondary effi  cacy outcomes at week 24
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analysis: adjusted mean change of 22·0 ms (placebo; 
n=38) versus 15·8 ms (opicinumab; n=37), a treatment 
diff erence versus placebo of −6·1 ms (95% CI −13·3 to 1·1; 
28% improvement; p=0·096) using ANCOVA analysis. 
Whether the reduced effi  cacy in the ITT population was 
due to the LOCF imputation or insuffi  cient treatment was 
unclear. However, results from this post-hoc analysis show 
that insuffi  cient treatment (ie, fewer than four treatments 
from baseline to 20 weeks) was the major contributor.
Among participants in the ITT population whose 
FF-VEP latency was impaired in the aff ected eye at 
baseline (defi ned as >3% worse than fellow eye or with 
conduction block), the number of participants with 
normal or mildly prolonged FF-VEP latency (defi ned as 
≤10% worse than fellow eye) at week 24 was 16 (53%) of 
30 in the opicinumab group and nine (26%) of 34 in the 
placebo group (p=0·028). At week 12, ten (29%) of 
35 participants in the opicinumab group and four (12%) 
of 33 participants in the placebo group had normal or 
mildly prolonged FF-VEP latency (p=0·094). Similar 
results were noted in the PP population with 15 (54%) of 
28 participants in the opicinumab group and nine (27%) 
of 33 participants in the placebo groups having normal 
or mildly prolonged FF-VEP latency at week 24 
(p=0·036) and nine (30%) of 30 participants in the 
opicinumab group and four (13%) of 31 participants in 
the placebo group at week 12 (p=0·10). Post-hoc 
sensitivity analyses done in the PP population showed 
that 10% was an appropriate cutoff  to indicate latency 
recovery (appendix p 9).
FF-VEP latency in the aff ected eye did not change over 
the course of the study, as shown in the appendix (p 10).
Discussion
Results of this study did not show a signifi cant diff erence 
in the change in FF-VEP latency at week 24 (primary 
endpoint) between the opicinumab and placebo groups 
in the ITT population. However, signifi cant diff erences 
were observed in the PP population at week 32.
RENEW is the fi rst multicentre randomised clinical 
trial investigating the effi  cacy of opicinumab and 
selected recovery of FF-VEP latency in the aff ected eye as 
the primary effi  cacy outcome. VEP latency is a sensitive 
measure of demyelination and subsequent remyelination 
in optic neuritis models.13–15 In participants presenting 
with an episode of acute optic neuritis, such as those 
enrolled in RENEW, baseline aff ected eye latency from 
demyelination cannot be assessed because of oedema 
and the frequent prevalence of conduction block. To 
overcome this limitation in the design of the RENEW 
study, we calculated the diff erence in aff ected eye VEP 
latency over time using the unaff ected fellow eye 
baseline value as the pretreatment normal reference 
value.12,16 Although variable between individuals,11 VEP 
usually has a very small inter-eye latency variation in the 
absence of disease pathology and is highly reproducible 
for sequential testing under standardised testing 
conditions.12,16,17 To ensure that the baseline of the fellow 
eye was normal, participants with a diagnosis of multiple 
sclerosis or ophthalmological disorders were excluded 
and the fellow eye had to have a normal VEP at screening.
In acute optic neuritis, infl ammation and optic nerve 
demyelination result in prolonged VEP latency; following 
acute optic neuritis, a number of processes, including 
infl ammation resolution earlier on and remyelination 
later on, result in incomplete VEP latency recovery over 
6 months.12,18,19 VEP has been used in animal models to 
assess neurological or potential eff ects on remyelination 
of the adenosine A1 receptor agonist N6-cyclohexyl-
adenosine and siRNAs against the Nogo receptor.20,21 VEP 
was also used in single or small multicentre clinical 
studies assessing high-dose intravenous immunoglobulin, 
erythropoietin, simvastatin, and phenytoin in patients 
with acute optic neuritis,22–25 and in natural recovery 
observational studies after an acute optic neuritis 
episode.12,16,17,26–28
When baseline characteristics of participants enrolled 
in RENEW were compared with those in trials of other 
candidate remyelinating or neuroprotective drugs, age 
and percentage of women were similar,7,22–25 whereas 
Placebo 
(n=41)
Opicinumab 
(n=41)
All participants 
(n=82)
Summary of adverse events
Any adverse event 34 (83%) 34 (83%) 68 (83%)
Serious adverse event 2 (5%) 5 (12%) 7 (9%)
Treatment-related serious adverse event 0 3 (7%) 3 (4%)
Discontinued treatment due to adverse event 1 (2%) 3 (7%) 4 (5%)
Withdrew from study due to adverse event 2 (5%) 3 (7%) 5 (6%)
Severity of events
Mild 12 (29%) 13 (32%) 25 (30%)
Moderate 20 (49%) 18 (44%) 38 (46%)
Severe 2 (5%) 3 (7%) 5 (6%)
Adverse events occurring in ≥10% of total participants
Nasopharyngitis 13 (32%) 12 (29%) 25 (30%)
Headache 11 (27%) 11 (27%) 22 (27%)
Fatigue 5 (12%) 6 (15%) 11 (13%)
Uhthoff ’s phenomenon 6 (15%) 3 (7%) 9 (11%)
Nausea 3 (7%) 5 (12%) 8 (10%)
Incidence by SOC for adverse events occurring in ≥10% of total participants*
Nervous system disorders 22 (54%) 22 (54%) 44 (54%)
Infections and infestations 22 (54%) 19 (46%) 41 (50%)
General disorders and administration site conditions 10 (24%) 9 (22%) 19 (23%)
Gastrointestinal disorders 5 (12%) 12 (29%) 17 (21%)
Eye disorders (other than the initial report of AON) 7 (17%) 8 (20%) 15 (18%)
Musculoskeletal and connective tissue disorders 7 (17%) 8 (20%) 15 (18%)
Skin and subcutaneous tissue disorders 7 (17%) 6 (15%) 13 (16%)
Investigations (abnormal clinical or laboratory test) 3 (7%) 6 (15%) 9 (11%)
Respiratory, thoracic, and mediastinal disorders 4 (10%) 4 (10%) 8 (10%)
SOC=System Organ Class. AON=acute optic neuritis. *A participant was counted only once within each SOC and 
preferred adverse event term. 
Table 3: Adverse events
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mean number of days from fi rst acute optic neuritis 
symptom to fi rst dose was 24 days in RENEW versus 
5–20 days in previous acute optic neuritis studies.7,22–25 A 
study testing erythropoietin reported shorter VEP 
latencies at week 16 for erythropoietin than for placebo, 
but the reported VEP latency was already shorter at 
baseline, resulting in an absence of treatment eff ect.23 A 
signifi cant eff ect on VEP latency was reported for 
simvastatin using imputation for not detectable baseline 
aff ected eye values, but not for intravenous 
immunoglobulin or phenytoin.22,24,25 When comparing 
these trials it should be noted that RENEW is a 
multicentre trial and was designed to overcome the 
limitation of not detectable baseline aff ected eye FF-VEP 
latency, by using the fellow healthy eye, and to use 
FF-VEP latency to determine change from baseline, with 
rigorous procedures for performance, central reading, 
and standardisation of latency measurement.
Outcome measures of remyelination were selected as 
the primary endpoints because the available preclinical 
data indicated a mechanism of action on this eff ect.2–4 
Because the effi  cacy of remyelination depends on axonal 
survival, we thought it was important to also investigate 
neuroprotective activity, even though effi  cacy on 
neuroprotection was hard to prove since it probably 
depends on very early administration of therapy.5 
Therefore, the study’s secondary endpoints investigated 
potential neuroprotection after acute infl ammatory 
injury to the RGC neurons as a result of acute optic 
neuritis, using SD-OCT and low-contrast letter acuity 
measures, and no eff ect of opicinumab was observed. 
However, the results showed that most retinal thinning 
occurred well before treatment started and all before the 
second dose (week 4). In view of the early occurrence of 
damage in acute optic neuritis, these data confi rm and 
highlight the need to intervene even sooner than we did 
in RENEW in future trials testing the neuroprotection of 
RGCs, and suggest treatment should begin within days 
rather than weeks after acute optic neuritis onset.25 This 
limited therapeutic intervention window for RGC 
protection was not seen for optic nerve remyelination, as 
evidenced from the observed VEP latency data with 
opicinumab. Hence, longer therapeutic intervention 
windows for remyelination should be explored with this 
and future candidate remyelinating agents. Notably, the 
clinical endpoints aff ected by the primary (VEP latency) 
and secondary (OCT) endpoints are currently not well 
understood. However, some data indicate that detection 
of motion tests correlate with VEP latency recovery and 
low-contrast letter acuity correlates with preservation of 
OCT endpoints.29,30
Acute optic neuritis without other brain lesions is 
known to have a lower risk of conversion to clinically 
defi nite multiple sclerosis than does acute optic neuritis 
with brain lesions,31 but little is known about diff erences 
or similarities in the severity of demyelination and extent 
of spontaneous remyelination in these two clinical 
scenarios. In RENEW, participants with and without 
other cerebral lesions were enrolled. Investigation of 
opicinumab as a remyelinating treatment for patients 
with multiple sclerosis and pre-existing lesions of longer 
duration was undertaken in the SYNERGY study 
(NCT01864148). This now completed trial investigated 
3 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg opicinumab 
given intravenously compared with placebo (19 doses) 
over 84 weeks in participants concurrently treated with 
30 μg intramuscular interferon beta-1a.
The safety analyses confi rmed that the overall incidence 
and severity of adverse events with opicinumab was 
similar to placebo. Three participants had serious adverse 
events reported as treatment related: two hypersensitivity 
reactions occurring shortly after the start of the second 
study drug infusion and one with an asymptomatic 
elevation in transaminases reported as hepatopathy. All 
three events resolved after treatment discontinuation. 
Weight gain greater than 7% was more frequent with 
opicinumab than with placebo and participants who had 
weight gain with opicinumab had worse baseline acute 
optic neuritis disease characteristics (data not shown). 
No evidence of weight gain was observed in previous 
clinical studies of opicinumab,10 but this adverse event 
merits further investigation in future studies. Overall, 
assessment of the safety of opicinumab is restricted by 
the relatively small and highly selected cohort and limited 
duration of exposure (32 weeks).
Although the dose used in RENEW is high for a 
monoclonal antibody (100 mg/kg compared with 150 mg 
for daclizumab and 300 mg for natalizumab32,33), it is 
much lower than the intravenous immunoglobulin dose 
used in the trial assessing remyelination following acute 
optic neuritis (400 mg/kg).22 For example, 100 mg/kg 
opicinumab provides a maximum mean concentration of 
2·7 mg/mL (SD 0·7) immuno globulin G,10 which is within 
the variability of normal total immunoglobulin G 
concentrations in adults (11·6 mg/mL [3·1]34). Notably, 
unlike intra venous immunoglobulin, opicinumab was 
specifi cally engineered to reduce eff ector function and 
complement activation (unpublished) so intravenous 
immunoglobulin-like eff ects are unlikely to explain the 
observed results.
Statistical signifi cance for FF-VEP latency was only 
reached in the PP population at week 32 (p=0·01). This 
might be explained by the sample size and hence power 
of this study being small and there was uncertainty at the 
time of the study design on the duration of therapeutic 
remyelination following acute optic neuritis. The sample 
size was simply an estimate because at study design the 
actual magnitude of the treatment eff ect of opicinumab 
was unknown. Also, the required treatment duration for 
optimal therapeutic remyelination, adequate balancing 
of baseline characteristics by randomisation, early 
terminations, and other actual events occurring in 
phase 2a trials with novel drugs such as opicinumab, are 
diffi  cult to predict, and all aff ect the actual power of the 
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study. These events include participants who withdrew 
from the study early because of adverse events at a time 
when latency delay can be severe, loss to follow-up, and 
withdrawal of consent, and applied to four (10%) 
participants in the placebo group and seven (17%) 
participants in the opicinumab group. Importantly, for 
imputation of missing data, in the ITT primary analysis 
the FF-VEP latency value at the last available visit was 
carried forward in the primary ANCOVA analysis at 
week 24. Based on the observed treatment eff ects, the 
actual power in this study was 16% for the ITT population 
and 58% for the PP population. Furthermore, the 
prespecifi ed analysis of effi  cacy on the primary endpoint 
at the individual level showed that the aff ected eye 
FF-VEP latency recovered to normal or near normal in 
twice as many participants treated with opicinumab than 
with placebo in both the ITT and PP populations, 
whereas the observed recovery rate with placebo was 
consistent with predictions from previous natural history 
studies with FF-VEP at less than 30%.17,19
Furthermore, the therapeutic intervention window to 
prevent retinal thinning was found to be small and very 
early in the disease course. These factors all restricted the 
ability to test the hypothesis of neuroprotection of RGCs 
with opicinumab following acute optic neuritis.
A major challenge in drug development is the 
translation of preclinical pharmacological observations 
into effi  cacy in human clinical trials. The fi ndings from 
the RENEW study suggest that enhancement of 
remyelination in the human CNS with opicinumab might 
be possible and provide valuable information about the 
design of subsequent studies. The results confi rm the 
feasibility of using participants with a fi rst acute optic 
neuritis episode as a target population to test novel CNS 
remyelinating and neuroprotective agents (also supported 
by the recent phenytoin study25), and FF-VEP latency as 
the primary biomarker endpoint in global studies of 
remyelinating therapies.5 Future trials with earlier 
administration of opicinumab following acute injury and 
with other CNS demyelinating lesions such as multiple 
sclerosis are needed to confi rm its use as a CNS 
remyelinating and neuroprotective drug candidate.
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